Literature DB >> 17202369

Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague.

Xinghong Yang1, B Joseph Hinnebusch, Theresa Trunkle, Catharine M Bosio, Zhiyong Suo, Mike Tighe, Ann Harmsen, Todd Becker, Kathryn Crist, Nancy Walters, Recep Avci, David W Pascual.   

Abstract

The gut provides a large area for immunization enabling the development of mucosal and systemic Ab responses. To test whether the protective Ags to Yersinia pestis can be orally delivered, the Y. pestis caf1 operon, encoding the F1-Ag and virulence Ag (V-Ag) were cloned into attenuated Salmonella vaccine vectors. F1-Ag expression was controlled under a promoter from the caf1 operon; two different promoters (P), PtetA in pV3, PphoP in pV4, as well as a chimera of the two in pV55 were tested. F1-Ag was amply expressed; the chimera in the pV55 showed the best V-Ag expression. Oral immunization with Salmonella-F1 elicited elevated secretory (S)-IgA and serum IgG titers, and Salmonella-V-Ag(pV55) elicited much greater S-IgA and serum IgG Ab titers than Salmonella-V-Ag(pV3) or Salmonella-V-Ag(pV4). Hence, a new Salmonella vaccine, Salmonella-(F1+V)Ags, made with a single plasmid containing the caf1 operon and the chimeric promoter for V-Ag allowed the simultaneous expression of F1 capsule and V-Ag. Salmonella-(F1+V)Ags elicited elevated Ab titers similar to their monotypic derivatives. For bubonic plague, mice dosed with Salmonella-(F1+V)Ags and Salmonella-F1-Ag showed similar efficacy (>83% survival) against approximately 1000 LD(50) Y. pestis. For pneumonic plague, immunized mice required immunity to both F1- and V-Ags because the mice vaccinated with Salmonella-(F1+V)Ags protected against 100 LD(50) Y. pestis. These results show that a single Salmonella vaccine can deliver both F1- and V-Ags to effect both systemic and mucosal immune protection against Y. pestis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17202369     DOI: 10.4049/jimmunol.178.2.1059

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  42 in total

Review 1.  Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.

Authors:  S Ramasamy; C Q Liu; H Tran; A Gubala; P Gauci; J McAllister; T Vo
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

2.  Α1-giardin based live heterologous vaccine protects against Giardia lamblia infection in a murine model.

Authors:  Gabriela Jenikova; Petr Hruz; Mattias K Andersson; Noa Tejman-Yarden; Patricia C D Ferreira; Yolanda S Andersen; Barbara J Davids; Frances D Gillin; Staffan G Svärd; Roy Curtiss; Lars Eckmann
Journal:  Vaccine       Date:  2011-10-12       Impact factor: 3.641

3.  Expression of Escherichia coli virulence usher protein attenuates wild-type Salmonella.

Authors:  Xinghong Yang; Zhiyong Suo; Theresa Thornburg; Kathryn Holderness; Ling Cao; Timothy Lim; Nancy Walters; Laura Kellerman; Linda Loetterle; Recep Avci; David W Pascual
Journal:  Virulence       Date:  2012-01-01       Impact factor: 5.882

4.  Efficient immobilization and patterning of live bacterial cells.

Authors:  Zhiyong Suo; Recep Avci; Xinghong Yang; David W Pascual
Journal:  Langmuir       Date:  2008-03-06       Impact factor: 3.882

5.  A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Xinghong Yang; Sarah Golden; Catharine M Bosio; Kathryn Crist; Todd Becker; Massimo Maddaloni; David W Pascual
Journal:  Infect Immun       Date:  2008-08-11       Impact factor: 3.441

Review 6.  Developing live vaccines against plague.

Authors:  Wei Sun; Kenneth L Roland; Roy Curtiss
Journal:  J Infect Dev Ctries       Date:  2011-09-14       Impact factor: 0.968

7.  An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague.

Authors:  Hitoki Yamanaka; Teri Hoyt; Richard Bowen; Xinghong Yang; Kathryn Crist; Sarah Golden; Massimo Maddaloni; David W Pascual
Journal:  Vaccine       Date:  2008-10-26       Impact factor: 3.641

8.  Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a Salmonella enterica serovar Typhimurium vaccine with regulated delayed antigen synthesis.

Authors:  Wei Xin; Soo-Young Wanda; Yuhua Li; Shifeng Wang; Hua Mo; Roy Curtiss
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

9.  Oral live vaccine strain-induced protective immunity against pulmonary Francisella tularensis challenge is mediated by CD4+ T cells and antibodies, including immunoglobulin A.

Authors:  Heather J Ray; Yu Cong; Ashlesh K Murthy; Dale M Selby; Karl E Klose; Jeffrey R Barker; M Neal Guentzel; Bernard P Arulanandam
Journal:  Clin Vaccine Immunol       Date:  2009-02-11

10.  Vaccination of mice with salmonella expressing VapA: mucosal and systemic Th1 responses provide protection against Rhodococcus equi infection.

Authors:  Aline F Oliveira; Luciana P Ruas; Silvia A Cardoso; Sandro G Soares; Maria-Cristina Roque-Barreira
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.